SEC Form 4 · accession 0001104659-16-131410

Syros Pharmaceuticals, Inc. · SYRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Period of report

Jul 6, 2016

Accepted (ET)

Jul 7, 2016 · 6:03 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001556263

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2,F3	Jul 6, 2016	C	84,760	—	A	84,760	D
Common Stock^F1,F2,F4	Jul 6, 2016	C	47,486	—	A	47,486	D
Common Stock^F1,F2,F5	Jul 6, 2016	C	262,069	—	A	262,069	D
Common Stock^F1,F2,F6	Jul 6, 2016	C	31,447	—	A	31,447	D
Common Stock^F1,F2,F7	Jul 6, 2016	C	40,420	—	A	40,420	D
Common Stock^F2,F4	Jul 6, 2016	P	144,383	$12.50	A	191,869	D
Common Stock^F2,F5	Jul 6, 2016	P	104,670	$12.50	A	366,739	D
Common Stock^F2,F6	Jul 6, 2016	P	174,320	$12.50	A	205,767	D
Common Stock^F2,F7	Jul 6, 2016	P	9,373	$12.50	A	49,793	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B Preferred Stock^F2,F3,F1	—	Jul 6, 2016	C	317,853	D	—	—	Common Stock	84,760	D
Series B Preferred Stock^F2,F4,F1	—	Jul 6, 2016	C	178,074	D	—	—	Common Stock	47,486	D
Series B Preferred Stock^F2,F5,F1	—	Jul 6, 2016	C	982,762	D	—	—	Common Stock	262,069	D
Series B Preferred Stock^F2,F6,F1	—	Jul 6, 2016	C	117,931	D	—	—	Common Stock	31,447	D
Series B Preferred Stock^F2,F7,F1	—	Jul 6, 2016	C	151,576	D	—	—	Common Stock	40,420	D

F1The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3These shares are owned directly by Redmile Biopharma Investments I, L.P.
F4These shares are owned directly by Redmile Capital Fund LP.
F5These shares are owned directly by Redmile Capital Offshore Fund II, Ltd.
F6These shares are owned directly by Redmile Capital Offshore Fund, Ltd.
F7These shares are owned directly by Redmile Special Opportunities Fund, Ltd.